These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 29924445

  • 1. Induction of strong immune response against a multicomponent antigen of Mycobacterium tuberculosis in BALB/c mice using PLGA and DOTAP adjuvant.
    Khademi F, Sahebkar A, Fasihi-Ramandi M, Taheri RA.
    APMIS; 2018 Jun; 126(6):509-514. PubMed ID: 29924445
    [Abstract] [Full Text] [Related]

  • 2. A novel antigen of Mycobacterium tuberculosis and MPLA adjuvant co-entrapped into PLGA:DDA hybrid nanoparticles stimulates mucosal and systemic immunity.
    Khademi F, Derakhshan M, Yousefi-Avarvand A, Najafi A, Tafaghodi M.
    Microb Pathog; 2018 Dec; 125():507-513. PubMed ID: 30352265
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity of HspX/EsxS fusion protein of Mycobacterium tuberculosis along with ISCOMATRIX and PLUSCOM nano-adjuvants after subcutaneous administration in animal model.
    Yousefi Avarvand A, Meshkat Z, Khademi F, Tafaghodi M.
    Microb Pathog; 2021 May; 154():104842. PubMed ID: 33762199
    [Abstract] [Full Text] [Related]

  • 4. Enhancing immunogenicity of novel multistage subunit vaccine of Mycobacterium tuberculosis using PLGA:DDA hybrid nanoparticles and MPLA: Subcutaneous administration.
    Khademi F, Yousefi A, Derakhshan M, Najafi A, Tafaghodi M.
    Iran J Basic Med Sci; 2019 Aug; 22(8):893-900. PubMed ID: 31579445
    [Abstract] [Full Text] [Related]

  • 5. Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection.
    Trentini MM, de Oliveira FM, Gaeti MP, Batista AC, Lima EM, Kipnis A, Junqueira-Kipnis AP.
    Vaccine; 2014 Jul 23; 32(34):4324-32. PubMed ID: 24951861
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
    Li Q, Yu H, Zhang Y, Wang B, Jiang W, Da Z, Xian Q, Wang Y, Liu X, Zhu B.
    Scand J Immunol; 2011 Jun 23; 73(6):568-76. PubMed ID: 21323695
    [Abstract] [Full Text] [Related]

  • 7. PLGA (85:15) nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects against Brucella abortus 544 infection: A promising alternate to traditional adjuvants.
    Singh D, Somani VK, Aggarwal S, Bhatnagar R.
    Mol Immunol; 2015 Dec 23; 68(2 Pt A):272-9. PubMed ID: 26442664
    [Abstract] [Full Text] [Related]

  • 8. The development and preliminary evaluation of a new Mycobacterium tuberculosis vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants.
    Chen L, Xu M, Wang ZY, Chen BW, Du WX, Su C, Shen XB, Zhao AH, Dong N, Wang YJ, Wang GZ.
    FEMS Immunol Med Microbiol; 2010 Jun 01; 59(1):42-52. PubMed ID: 20298499
    [Abstract] [Full Text] [Related]

  • 9. Fused Mycobacterium tuberculosis multi-stage immunogens with an Fc-delivery system as a promising approach for the development of a tuberculosis vaccine.
    Mosavat A, Soleimanpour S, Farsiani H, Sadeghian H, Ghazvini K, Sankian M, Jamehdar SA, Rezaee SA.
    Infect Genet Evol; 2016 Apr 01; 39():163-172. PubMed ID: 26835592
    [Abstract] [Full Text] [Related]

  • 10. Enhancement of immune response against Mycobacterium tuberculosis HspX antigen by incorporation of combined molecular adjuvant (CASAC).
    Lew MH, Norazmi MN, Tye GJ.
    Mol Immunol; 2020 Jan 01; 117():54-64. PubMed ID: 31739193
    [Abstract] [Full Text] [Related]

  • 11. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice.
    Bivas-Benita M, Lin MY, Bal SM, van Meijgaarden KE, Franken KL, Friggen AH, Junginger HE, Borchard G, Klein MR, Ottenhoff TH.
    Vaccine; 2009 Jun 19; 27(30):4010-7. PubMed ID: 19389445
    [Abstract] [Full Text] [Related]

  • 12. CpG7909 adjuvant enhanced immunogenicity efficacy in mice immunized with ESAT6-Ag85A fusion protein, but does not confer significant protection against Mycobacterium tuberculosis infection.
    Hu S, Chen H, Ma J, Chen Q, Deng H, Gong F, Huang H, Shi C.
    J Appl Microbiol; 2013 Nov 19; 115(5):1203-11. PubMed ID: 23902541
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Enhancement of the immunogenicity of a Mycobacterium tuberculosis fusion protein using ISCOMATRIX and PLUSCOM nano-adjuvants as prophylactic vaccine after nasal administration in mice.
    Yousefi Avarvand A, Meshkat Z, Khademi F, Aryan E, Sankian M, Tafaghodi M.
    Iran J Basic Med Sci; 2024 Nov 19; 27(1):24-30. PubMed ID: 38164481
    [Abstract] [Full Text] [Related]

  • 15. Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model.
    Alipour Talesh G, Ebrahimi Z, Badiee A, Mansourian M, Attar H, Arabi L, Jalali SA, Jaafari MR.
    Immunol Lett; 2016 Aug 19; 176():57-64. PubMed ID: 27260485
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and protective efficacy of multistage vaccine candidates (Mtb8.4-HspX and HspX-Mtb8.4) against Mycobacterium tuberculosis infection in mice.
    Liu W, Li J, Niu H, Lin X, Li R, Wang Y, Xin Q, Yu H, Wu Y, Zhu B, Tan J.
    Int Immunopharmacol; 2017 Dec 19; 53():83-89. PubMed ID: 29045910
    [Abstract] [Full Text] [Related]

  • 17. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNFα-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis.
    Margaroni M, Agallou M, Athanasiou E, Kammona O, Kiparissides C, Gaitanaki C, Karagouni E.
    Int J Nanomedicine; 2017 Dec 19; 12():6169-6184. PubMed ID: 28883727
    [Abstract] [Full Text] [Related]

  • 18. Poly(d,l)-lactide-co-glycolide (PLGA) microspheres as immunoadjuvant for Brugia malayi antigens.
    Saini V, Verma SK, Murthy PK, Kohli D.
    Vaccine; 2013 Aug 28; 31(38):4183-91. PubMed ID: 23827312
    [Abstract] [Full Text] [Related]

  • 19. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R, Muto S, Iwata T, Hidaka A, Kiyono H, Kunisawa J, Aramaki Y.
    BMC Res Notes; 2017 Jan 26; 10(1):68. PubMed ID: 28126014
    [Abstract] [Full Text] [Related]

  • 20. APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice.
    Soleimanpour S, Farsiani H, Mosavat A, Ghazvini K, Eydgahi MR, Sankian M, Sadeghian H, Meshkat Z, Rezaee SA.
    Appl Microbiol Biotechnol; 2015 Dec 26; 99(24):10467-80. PubMed ID: 26373723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.